Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Janice M. Mehnert, MD

Professor of Medicine
NYU Grossman School of Medicine
Associate Director for Clinical Research
Laura and Isaac Perlmutter Cancer Center at NYU
Director
Melanoma and Cutaneous Medical Oncology
New York, New York

Disclosures

Janice M. Mehnert, MD, has the following relevant financial relationships:
Consultant or advisor for: Merck
Speaker or member of speakers bureau for: Bristol Myers Squibb Company; Eisai, Inc.; Novartis; Regeneron Pharmaceuticals, Inc.; Seagen, Inc.
Research funding from: Bristol Myers Squibb Company; Incyte Corporation; Kinnate; Merck; Novartis
Stock options from: Pfizer, Inc.
Owns stock (publicly traded) in: Pfizer, Inc.

Editor

Deborah Middleton, MS

Senior Medical Education Director, WebMD Global, LLC

Disclosures

Deborah Middleton, MS, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

Assess Your Understanding of Immune Checkpoint Inhibitors in Metastatic Melanoma

Authors: Janice M. Mehnert, MD
CME / ABIM MOC Released: 1/13/2023
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 1/13/2024, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, dermatologists, pathologists, surgeons, and other members of the multidisciplinary team.

The goal of this activity is for learners to be better able to understand the spectrum of immune checkpoint inhibitors (ICIs) used in the frontline management of metastatic melanoma.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Therapeutic management strategies involving ICIs for the treatment of patients with metastatic melanoma
Self-assess learning needs related to
- Best practices for integrating ICIs for the treatment of metastatic melanoma

Disclosures

Faculty

Janice M. Mehnert, MD

Professor of Medicine
NYU Grossman School of Medicine
Associate Director for Clinical Research
Laura and Isaac Perlmutter Cancer Center at NYU
Director
Melanoma and Cutaneous Medical Oncology
New York, New York

Disclosures

Janice M. Mehnert, MD, has the following relevant financial relationships:
Consultant or advisor for: Merck
Speaker or member of speakers bureau for: Bristol Myers Squibb Company; Eisai, Inc.; Novartis; Regeneron Pharmaceuticals, Inc.; Seagen, Inc.
Research funding from: Bristol Myers Squibb Company; Incyte Corporation; Kinnate; Merck; Novartis
Stock options from: Pfizer, Inc.
Owns stock (publicly traded) in: Pfizer, Inc.

Editor

Deborah Middleton, MS

Senior Medical Education Director, WebMD Global, LLC

Disclosures

Deborah Middleton, MS, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Assess Your Understanding of Immune Checkpoint Inhibitors in Metastatic Melanoma

Authors: Janice M. Mehnert, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 1/13/2023

Valid for credit through: 1/13/2024, 11:59 PM EST

processing....

The goals of continuing medical education (CME) and professional development are to acquire and retain knowledge that will enhance clinical practice and improve patient outcomes. The following self-assessment survey is offered for CME credit and is designed to test your current knowledge and skills related to melanoma.

Page 1 of 7

CME / ABIM MOC Information

Print
Like Tweet

References

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Janice M. Mehnert, MD

Editor

Deborah Middleton, MS

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC

Assess Your Understanding of Immune Checkpoint Inhibitors in Metastatic Melanoma

Target Audience and Goal Statement

Disclosures

Faculty

Janice M. Mehnert, MD

Editor

Deborah Middleton, MS

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Assess Your Understanding of Immune Checkpoint Inhibitors in Metastatic Melanoma